Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pediatric hematopoietic stem cell transplantation.

T G Gross1, R M Egeler, F O Smith

  • 1Division of Hematology/Oncology, Blood and Marrow Transplantation Program, Children's Hospital Medical Center, Cincinnati, Ohio, USA. grob8x@chmcc.org

Hematology/Oncology Clinics of North America
|January 5, 2002
PubMed
Summary

Allogeneic hematopoietic stem cell transplantation (HSCT) in children faces challenges like GVHD and infections. Advances in HSC sources are promising, but further research into transplant biology and complications is crucial for improved therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.

Bone marrow transplantation·2016
Same author

Despite differential gene expression profiles pediatric MDS derived mesenchymal stromal cells display functionality in vitro.

Stem cell research·2015
Same author

Major ABO incompatible BMT in children: determining what residual volume of donor red cells can safely be infused following red cell depletion.

Bone marrow transplantation·2015
Same author

Patient reported outcomes in pediatric oncology practice: suggestions for future usage by parents and pediatric oncologists.

Pediatric blood & cancer·2014
Same author

Second malignancies after autologous hematopoietic cell transplantation in children.

Bone marrow transplantation·2012
Same author

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.

Leukemia·2012

Area of Science:

  • Pediatric Hematology and Oncology
  • Transplantation Immunology

Background:

  • Allogeneic hematopoietic stem cell transplantation (HSCT) is vital for treating pediatric malignant and nonmalignant diseases.
  • Current HSCT success in children is hindered by graft-versus-host disease (GVHD), infections, immune recovery delays, toxicity, and disease relapse.

Purpose of the Study:

  • To review the current limitations and future directions in pediatric allogeneic HSCT.
  • To highlight the importance of understanding HSC biology, GVHD, immune reconstitution, and complications for therapeutic advancement.

Main Methods:

  • This review synthesizes current knowledge on pediatric allogeneic HSCT.
  • It focuses on challenges, recent advances, and future research needs.

Main Results:

Related Experiment Videos

  • Significant progress has been achieved in identifying suitable hematopoietic stem cell (HSC) sources.
  • Key challenges remain, including GVHD, infectious complications, and immune system recovery.

Conclusions:

  • Future improvements in pediatric HSCT depend on a deeper understanding of HSC biology, GVHD mechanisms, immune reconstitution, and common transplant complications.
  • Enhanced patient participation in translational and clinical studies is essential for developing better therapies.